Trial Profile

Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adults, Adolescents, Children, and Toddlers in India and Healthy Adolescents and Children in the Republic of South Africa

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 23 Jan 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Meningococcal vaccine groups A C Y W-135 conjugate (Primary) ; Meningococcal-polysaccharide-vaccine-groups-ACYW135-Bio-Med
Indications Meningococcal group A infections; Meningococcal group C infections; Meningococcal group W-135 infections; Meningococcal group Y infections
Focus Pharmacodynamics; Registrational
Acronyms MET55
Sponsors Sanofi Pasteur

13 Nov 2023 Status changed from recruiting to completed.
04 Jan 2023 Planned End Date changed from 14 Sep 2023 to 12 Jul 2024.
04 Jan 2023 Planned primary completion date changed from 14 Sep 2023 to 12 Jul 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com